George Agyapong
MD, MS, BSc (Hon)
Hospital Resident
Research & Publications
Biography
News
Selected Publications
- Molecular characterization and cell type composition deconvolution of fibrosis in NAFLDPantano L, Agyapong G, Shen Y, Zhuo Z, Fernandez-Albert F, Rust W, Knebel D, Hill J, Boustany-Kari C, Doerner J, Rippmann J, Chung R, Ho Sui S, Simon E, Corey K. Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD Scientific Reports 2021, 11: 18045. PMID: 34508113, PMCID: PMC8433177, DOI: 10.1038/s41598-021-96966-5.
- Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLDFourman LT, Billingsley JM, Agyapong G, Sui S, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD JCI Insight 2020, 5: e140134. PMID: 32701508, PMCID: PMC7455119, DOI: 10.1172/jci.insight.140134.
- A Teaching Case on Option B-Plus in Malawi: Toward Locally Inspired Global Health TrainingAgyapong, George. 2020. A Teaching Case on Option B-Plus in Malawi: Toward Locally Inspired Global Health Training. Doctoral dissertation, Harvard Medical School.
- The Discovery and Development of Thienopyrimidines as Inhibitors of Helicobacter pylori That Act through Inhibition of the Respiratory Complex IMugengana AK, Vita NA, Gandt A, Moran K, Agyapong G, Sharma LK, Griffith EC, Liu J, Yang L, Gavrish E, Hevener KE, LaFleur MD, Lee RE. The Discovery and Development of Thienopyrimidines as Inhibitors of Helicobacter pylori That Act through Inhibition of the Respiratory Complex I ACS Infectious Diseases 2021, 7: 1044-1058. PMID: 33471519, PMCID: PMC8122083, DOI: 10.1021/acsinfecdis.0c00300.
- Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD.Pantano, L., Agyapong, G., Shen, Y. et al. Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. Sci Rep 11, 18045 (2021). https://doi.org/10.1038/s41598-021-96966-5
- A rare case of idiopathic cholestasis: Clinical conundrums complicating enzalutamide therapy in metastatic prostate cancerLiu J, Agyapong G, Misra D, Taylor CD, Hirsh DA. A rare case of idiopathic cholestasis: Clinical conundrums complicating enzalutamide therapy in metastatic prostate cancer Clinical Case Reports 2019, 7: 2068-2073. PMID: 31788253, PMCID: PMC6878062, DOI: 10.1002/ccr3.2427.
- Erratum to: Probiotic Therapy for Treating Behavioral and Gastrointestinal Symptoms in Autism Spectrum Disorder: A Systematic Review of Clinical TrialsLiu J, Wan GB, Huang MS, Agyapong G, Zou TL, Zhang XY, Liu YW, Song YQ, Tsai YC, Kong XJ. Erratum to: Probiotic Therapy for Treating Behavioral and Gastrointestinal Symptoms in Autism Spectrum Disorder: A Systematic Review of Clinical Trials Current Medical Science 2019, 39: 512-512. PMID: 31209825, DOI: 10.1007/s11596-019-2066-7.
- Probiotic Therapy for Treating Behavioral and Gastrointestinal Symptoms in Autism Spectrum Disorder: A Systematic Review of Clinical TrialsLiu J, Wan GB, Huang MS, Agyapong G, Zou TL, Zhang XY, Liu YW, Song YQ, Tsai YC, Kong XJ. Probiotic Therapy for Treating Behavioral and Gastrointestinal Symptoms in Autism Spectrum Disorder: A Systematic Review of Clinical Trials Current Medical Science 2019, 39: 173-184. PMID: 31016507, DOI: 10.1007/s11596-019-2016-4.
- In Vitro Study of a Medical Device to Enhance Arteriovenous Fistula Eligibility and MaturationLoree HM, Agyapong G, Favreau EG, Ngai GA, Tansley GD, Dixon BS, Franano FN. In Vitro Study of a Medical Device to Enhance Arteriovenous Fistula Eligibility and Maturation ASAIO Journal 2015, 61: 480-486. PMID: 26120958, DOI: 10.1097/mat.0000000000000240.